- First patient in the world treated with Alpha DaRT® in the brain – - According to the National Brain…
93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…
December 07, 2025 16:00 ET | Source: Wave Life Sciences USA, Inc. CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) --…
December 06, 2025 17:30 ET | Source: TScan Therapeutics, Inc. Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23)…
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…
NEWTON, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- 4D Path, a company dedicated to personalizing cancer care through a novel,…
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases,…
The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift…
November 18, 2025 16:30 ET | Source: Protara Therapeutics NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.…
November 09, 2025 09:00 ET | Source: Medera Inc. BOSTON, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a…